Showing 2801-2810 of 3415 results for "".
- FDA Approves Topical Ruxolitinib for AD in Children Aged 2 and Uphttps://practicaldermatology.com/news/fda-approves-topical-ruxolitinib-for-ad-in-children-aged-2-and-up/2483445/The US Food and Drug Administration (FDA) has approved ruxolitinib cream 1.5% (Opzelura) for the short-term and non-continuous chronic treatment of mild-to-moderate atopic dermatitis (AD) in non-immunocompromised children ages 2 and older whose disease is inadequate
- FDA Clears IND for Rubedo’s GPX4 Modulator in Actinic Keratosishttps://practicaldermatology.com/news/fda-clears-ind-for-rubedos-gpx4-modulator-in-actinic-keratosis/2483388/Rubedo Life Sciences has received FDA clearance for a second Investigational New Drug (IND) application for its lead compound RLS-1496, enabling a Phase 1b/2a trial in patients with actinic keratosis to begin in Q4 2025. Accordi
- Arcutis Seeks FDA Greenlight to Expand ZORYVE for Children Under 6https://practicaldermatology.com/news/arcutis-seeks-fda-greenlight-to-expand-zoryve-for-children-under-6/2483230/Arcutis Biotherapeutics has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to expand the indication of ZORYVE® (roflumilast) cream 0.3% for the treatment of plaque psoriasis in children aged 2 to 5, according to
- Switching Biologics for Psoriasis May Improve Outcomes Without Added Risk: Studyhttps://practicaldermatology.com/news/switching-biologics-for-psoriasis-may-improve-outcomes-without-added-risk-study/2476064/Plaque psoriasis patients who are unresponsive to initial biologics may derive benefit from switching to another drug class, according to a new meta-analysis of 24 randomized controlled trials (RCTs). The review looked at da
- Deucravacitinib Plus Topical C/BD Effective in Moderate to Severe Psoriasis: Analysishttps://practicaldermatology.com/news/deucravacitinib-plus-topical-cbd-effective-in-moderate-to-severe-psoriasis-analysis/2476009/New research in the Journal of Drugs in Dermatology suggests that adding topical calcipotriene/betamethasone dipropionate (C/BD) foam to oral deucravacitinib therapy improves outcomes and quality of life in patients with moderate to severe chronic plaque p
- Report: IL-17 Therapies Target PsO and More, Poised for Growthhttps://practicaldermatology.com/news/report-il-17-therapies-target-pso-and-more-poised-for-growth/2475920/The interleukin-17 (IL-17) inhibitors market is expected to see sustained growth through 2034, driven primarily by next-gen agents and expanding indications in dermatology and rheumatology, according to a new report. Novel ag
- FDA Greenlights First Treatment for Chronic Hand Eczema in Adultshttps://practicaldermatology.com/news/fda-approves-first-treatment-for-chronic-hand-eczema-in-adults/2475816/The US Food and Drug Administration (FDA) has approved ANZUPGO® (delgocitinib) cream, making it the first and only treatment approved for adults with moderate-to-severe chronic hand eczema (CHE) who are unresponsive to topical corticosteroids or for those unsuitabl
- Analysis Concludes No Single Preclinical Model Fully Mimics Human PsOhttps://practicaldermatology.com/news/Analysis-Concludes-No-Single-Preclinical-Model-Fully-Mimics-Human-PsO/2475576/Despite extensive preclinical model development, no single system fully mimics human psoriatic disease, according to a new analysis published in Expert Opinion on Drug Discovery. Researchers on the study emphasized the importance of preclinical models that can reproduce disease-re
- Study: Iron Oxide Formulation Improved Radiance in Melasma-Prone Skinhttps://practicaldermatology.com/news/study-feo-formulation-improves-radiance-in-melasma-prone-skin/2475517/A new study published in Journal of Drugs in Dermatology evaluated the incorporation of iron oxide (FeO) into a daily sun care routine could offer protection and any benefit for patients with melasma and photodamage.
- SKINVIVE sPMA Accepted for Neck Line Treatmenthttps://practicaldermatology.com/news/skinvive-spma-accepted-for-neck-line-treatment/2475452/The U.S. Food and Drug Administration (FDA) has accepted for review a supplemental premarket approval (sPMA) application from Allergan Aesthetics, an AbbVie company, for SKINVIVE by JUVÉDERM® for the treatment of neck lines in adults, according to a press release.<